The headlines say these drugs “eat muscle.” The trial data say something more precise: the proportion of lean tissue lost is ordinary for weight loss, but the kilograms are not trivial, and what you do about them matters more than protein alone.
The ratio is normal. The kilograms are not trivial.

Lean-mass loss on GLP-1 medicines is real. Across the body-composition studies, roughly a quarter to two-fifths of the weight lost is lean mass rather than fat. But that proportion is not a drug-specific wasting effect: in the largest pooled analysis to date, 20 randomized trials, 15,782 participants, lean mass was 25 to 39% of weight lost on incretin therapies and 26.2% with intensive lifestyle intervention, a difference that was not statistically significant (p = 0.42). The authors’ conclusion was blunt: lean loss is “a physiological consequence of weight reduction, not a disproportionate drug effect.”[1]
No evidence shows the drugs attack muscle directly. The mechanism is the energy deficit itself, plus appetite suppression and less mechanical loading as body weight falls. On MRI, muscle-volume change on tirzepatide matched the population-expected change for the weight lost.[2]
So why does this deserve a whole article? Because of scale. A lifestyle program that produces 6 kg of weight loss at a 26% lean share costs about 1.5 kg of lean tissue. A GLP-1 producing 20 kg of loss at the same share costs more than 5 kg, an amount comparable to a decade or more of age-related muscle loss, arriving in a little over a year. For a robust 45-year-old, that is usually manageable. For a 72-year-old who starts with little muscle in reserve, it may not be.
Not “GLP-1s eat muscle” and not “muscle loss is a myth.” It is this: the proportion lost is the same as with any effective weight loss; the absolute amount is large because the total weight loss is large, and the people with the least muscle to spare are the ones who need a plan, not just a prescription.
First, a distinction the headlines skip: lean mass is not muscle
Almost every alarming number in this debate comes from DXA scans, and DXA does not measure muscle. It divides the body into fat mass, bone mineral, and everything else. That “everything else” is called lean mass or lean soft tissue. It includes skeletal muscle but also water, organs, connective tissue, and the water stored with glycogen.[3]
The 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society estimates that muscle is only about half of lean mass. So when a trial reports that 38% of weight lost was lean, the muscle share is roughly 20%. The headline overstates muscle loss about twofold. Modeled without structured strength training, the advisory puts muscle at about 10 to 15% of weight lost in women and 20 to 25% in men.[4]
What a DXA calls “lean mass”
Roughly half of lean soft tissue is skeletal muscle. The rest is water, organs, connective tissue and glycogen-associated water, some of which shrinks appropriately as the body gets smaller.
What that means for a “38% lean” headline
STEP-1’s ~38% lean share translates to roughly 20% of total weight lost as actual muscle (about 19% muscle, 19% other lean tissue), still meaningful, but half the headline figure.
Two more measurement caveats matter. Some early lean loss is glycogen and water, which is partly reversible and is not contractile tissue. And DXA cannot tell whether lean tissue was lost from the limbs, where it affects strength and function, or from the trunk and organs. MRI measures of thigh and appendicular muscle are better, and trials are only now using them.
STEP-1: semaglutide
In the DXA substudy of STEP-1 (n = 140), semaglutide 2.4 mg over 68 weeks reduced fat mass by 19.3% and lean body mass by 9.7%, while the lean proportion of the body actually rose by 3.0 percentage points. People became leaner overall even as they lost lean tissue in absolute terms. The joint advisory summarizes the substudy as a 13.6 kg loss made up of 8.3 kg of fat (62%) and 5.3 kg of lean (38%).[4]
A second published summary of the same substudy (Look et al., 2025) reports 10.4 kg of fat and 6.9 kg of lean, 60% fat / 40% lean. The percentages agree (~38 to 40% lean); the kilograms differ, likely because of different samples or estimands. Some reviews quote 45% lean for STEP-1, but that figure traces to a review tabulation rather than the primary paper and could not be reconciled to a primary source. This article uses about 38 to 40% and cites both summaries rather than picking one silently.
SURMOUNT-1: tirzepatide
The SURMOUNT-1 DXA substudy (n = 160 with baseline and week-72 scans; 73% women, mean age 46) is the cleanest dataset we have. On tirzepatide, weight fell 21.3%, fat mass fell 33.9% (−15.9 kg), and lean mass fell 10.9% (−5.6 kg). The split of weight lost was 74% fat / 26% lean, essentially identical to placebo’s 75% / 25%, despite roughly four times the total loss. Visceral fat fell 40.1%. The proportions were consistent across age groups (including ≥65 years, at 76% fat), sex, dose, and weight-loss tertiles.[3]
One caution: STEP-1 and SURMOUNT-1 are different trials, with different populations, scanners and durations. There is no randomized head-to-head DXA trial, so do not read these numbers as proof that one drug is gentler on muscle than the other. The pooled analysis below is the fairer comparison, and even it is indirect.
Lean mass as a share of weight lost, by approach
Pooled estimates with 95% confidence intervals, Eisa & Barood, 2026 (20 RCTs, 15,782 participants)
Whiskers show 95% confidence intervals. Heterogeneity across trials was substantial (I² = 68%), and a separate meta-analysis of nine placebo-controlled DXA trials (Beavers et al., 2025) put the lean share at about 30% overall.[5] Individual trials range widely, from ~15% or less to 40 to 60% in some studies, depending on population, drug and comorbidity.
Estimate your own split
Pick a total weight loss and an approach. The lean share comes from the pooled analysis above; estimated muscle assumes muscle is about half of lean mass, per the joint advisory. This is a population-level model, not a prediction for an individual. Your own split depends on training, protein, rate of loss and starting composition.
For context, the advisory’s sex-specific modeling, without structured strength training, puts muscle at about 10 to 15% of weight lost in women and 20 to 25% in men. Resistance training is what moves you toward the bottom row of the chart above.
GLP-1s are not worse than the alternatives. They are bigger.
Every method that produces large weight loss takes lean tissue with it. Diet-only weight loss has followed a rough “quarter rule” for decades: about 20 to 30% of the loss is fat-free mass, and the degree of caloric restriction and the speed of loss push that share up, as a systematic review of 55 cohorts showed back in 2007.[6] Bariatric surgery sits in the same band. GLP-1s do too.
So why does lean loss feel worse on GLP-1s? Three reasons, none of them a unique drug toxicity. First, total loss matches what surgery produces, 15 to 22% of body weight versus 5 to 10% for most lifestyle programs, so the same percentage means 5 to 6 kg of lean tissue instead of 1 to 2 kg. Second, the loss is fast, especially during dose titration. Third, appetite suppression can drive protein intake very low at exactly the time the body needs it most.
There is one more pattern worth knowing: the leaner you get, the worse the ratio tends to become. In SURMOUNT-1, the group that lost the least weight had the lowest fat share (70%), and as fat stores shrink the body defends them and takes proportionally more from lean tissue. That is an argument for lifting harder late in a weight loss, not just at the start.
Strength is mostly preserved, until you test it properly
The reassuring version of the story has real evidence behind it. A 2026 narrative review of 21 studies in older adults found GLP-1 therapy associated with muscle-mass loss in most studies but generally without significant changes in strength, with muscle quality mostly improved. In SURMOUNT-1, patient-reported physical function improved on tirzepatide despite the lean loss, carrying 20 fewer kilograms makes daily function easier even with somewhat less muscle. And on MRI in SURPASS-3, tirzepatide reduced the fat infiltrating muscle by 0.36 percentage points: less muscle, but cleaner muscle.[2][7]
The counterpoint is the sharpest data in this article. In the T-REx trial (below), adults aged 50 to 70 on tirzepatide without training lost 6 to 9% of their strength over 40 weeks. Bench press fell 8.4%. So “strength is preserved” is true on average in younger trial populations, and false without training in the one trial that measured strength directly in this age group. Both statements are in the literature; which one applies to you depends on your age, your reserve, and whether you train.
Who is actually at risk
Aging alone removes roughly 3 to 8% of muscle mass per decade after 30, faster after 60, and strength falls faster than mass. Starting reserve is therefore the key variable. The joint advisory identifies as especially vulnerable: older adults, peri- and postmenopausal women, sedentary people, and anyone not doing strength training.[4] In SURMOUNT-1’s ≥65 subgroup the fat share was 76%, no disproportionate lean loss, but that subgroup was small and not frail, and the trial authors still flag older adults at risk of sarcopenic obesity as needing individualized nutrition and activity plans.
Scale matters too. Someone who loses 30 kg at a 25% lean share loses 7.5 kg of lean tissue, roughly the muscle lost over a decade or more of aging, and after 65, anabolic resistance makes it harder to rebuild. There is also a plausible ratchet: stop the drug, regain weight that is predominantly fat, and repeat, each cycle leaving less muscle than the last. That mechanism is a hypothesis, not something yet proven in GLP-1 cohorts, and the body composition of weight regain on modern GLP-1s is understudied.
What about mortality?
Sarcopenia itself is strongly linked to death: a meta-analysis of 56 studies and 42,108 participants found sarcopenia associated with roughly double the mortality risk (HR 2.00, 95% CI 1.71 to 2.34).[8] But that is prevalent sarcopenia, low mass plus low strength and function, often alongside illness, in older populations. Applying that hazard ratio to a person with obesity who lost 5 kg of lean tissue while gaining function and metabolic health is not valid, and no honest reading of the data does so.
The counterweight is proven benefit. In SELECT, semaglutide 2.4 mg in 17,604 adults with cardiovascular disease and overweight or obesity cut major cardiovascular events from 8.0% to 6.5% (HR 0.80) over about 40 months. No GLP-1 outcomes trial has shown a mortality increase attributable to lean loss. The honest statement is this: the cardiovascular benefit is proven in high-risk adults; a mortality harm from the accompanying lean loss is hypothesized, not demonstrated, and the balance plausibly flips in frail, low-reserve older adults, where the benefit is less certain and the muscle cost more dangerous.
No GLP-1 trial has had falls, fractures or frailty as a primary outcome, and no study establishes a “safe” threshold for lean loss. A large preprint meta-analysis (not peer reviewed) found no increase in serious falls or fractures, but it captured only serious adverse events in trial populations whose mean ages topped out around 74, not the frailest old. Whether GLP-1 lean loss causes falls or frailty in the people most at risk remains an open question, not a settled reassurance.
Beyond protein: training is the intervention, protein is the support
Most advice on this topic starts and ends with protein. The evidence orders things differently. Resistance training is the only strategy with a direct randomized trial on a modern GLP-1, and protein, in the joint advisory’s own words, is “likely inadequate” on its own without structured resistance training. Here is the protection plan in evidence order.
1. Resistance training: the T-REx trial
T-REx (Green et al., Nature Medicine, November 2026) randomized 120 sedentary adults aged 50 to 70, all on tirzepatide titrated to 15 mg, to thrice-weekly supervised resistance training or usual activity for 40 weeks, with 91% adherence in the training group. Total weight loss was identical. Almost everything else was not.[9]
Without training, tirzepatide alone cost 4.67 kg of lean soft tissue and 6 to 9% of strength across the three lifts. Bars are centred on zero: left is loss, right is gain (strength bars show percent change, capped for display).
Read that carefully, because it cuts both ways. Training saved about 1.1 kg of lean tissue, roughly a quarter less lean loss, and swung strength by about 20 percentage points, from losing 6 to 9% to gaining 10 to 18%. But training did not fully prevent lean loss: even the lifters lost 3.6 kg. The trial ran at a single center (Perth), in people aged 50 to 70 without diabetes, over 40 weeks, with no falls or function endpoints and no follow-up after stopping. It is the best evidence we have, and it says: train, and expect attenuation, not immunity.
Earlier work points the same way. In the S-LiTE trial, after an initial diet-induced loss, the combination of supervised exercise plus liraglutide maintained a 9.5 kg loss at one year, better than either alone, and cut body-fat percentage by 3.9 points, about twice either single treatment. A year after all treatment stopped, the former combination group was still 5.1 kg lighter and 2.3 points leaner than the former liraglutide-only group, and the exercise groups were the only ones still holding a ≥10% loss on average.[10] Carry the caveats with those numbers: only 109 of 195 participants returned for the follow-up, the exercise was supervised and vigorous, the drug was liraglutide (older and weaker), and the initial loss came from diet. The finding is about having built an exercise habit, not a post-stopping prescription proven in its own trial. And in adults over 65 losing weight by diet (Villareal 2017), resistance training limited lean loss to 2% versus 5% with aerobic exercise alone, while also halving hip bone-density loss.
The dose: the joint advisory recommends strength training at least 3 times per week plus at least 150 minutes per week of moderate aerobic activity; general guidance sets muscle-strengthening on at least 2 days per week as a floor. Treat 2×/week as the minimum and 3×/week, the T-REx dose, as the target.
2. Protein: necessary, proposed, and not proven on these drugs
The joint advisory proposes 1.2 to 1.6 g of protein per kilogram of body weight per day during active weight loss, well above the 0.8 g/kg RDA, which is a minimum to prevent deficiency, not a target for someone losing 20 kg. A practical alternative the advisory gives is an absolute 80 to 120 g/day. It also sets a floor: do not fall below 0.4 to 0.5 g/kg/day, a range associated with muscle atrophy and functional impairment, and avoid prolonged intakes at or above 2 g/kg/day.[4]
Protein target calculator
Two honest caveats. First, the advisory itself says it is unclear which weight to use, and that actual body weight can significantly overestimate requirements in obesity. Adjusted or ideal weight, or fat-free mass, are listed alternatives, which is why the basis selector exists. Second, the 1.2 to 1.6 g/kg figure is proposed, borrowed from weight-loss, aging and bariatric research. It has not been established in prospective trials in GLP-1 users. Kidney disease and other conditions require individualized targets; this calculator is a starting point for a conversation, not a prescription.
The practical problem is rarely knowledge. It is intake. Appetite suppression and nausea can make even 80 g/day hard during titration. That is one reason side-effect management, meal timing, and protein-first eating are part of muscle protection, even though none of them has a GLP-1-specific muscle trial behind it.
3. Everything else, graded honestly
- 1
Resistance training, 2 to 3 times per weekDirect RCT evidence
T-REx on tirzepatide, plus S-LiTE and Villareal by extension. The only intervention shown to change both lean loss and strength on a modern GLP-1. It attenuates loss; it does not abolish it.
- 2
Protein at 1.2 to 1.6 g/kg/dayProposed advisory target
Recommended by the four-society joint advisory, borrowed from adjacent literature. Supports training; the advisory is explicit that protein without structured resistance training is likely inadequate on its own.
- 3
Keep the rate near 0.5 to 1% of body weight per weekExtrapolated
In athletes, losing at 0.7%/week preserved or gained lean mass while 1.4%/week cost lean mass and strength, and restriction degree predicts the fat-free share of loss. No trial has randomized fast versus slow loss on a GLP-1 and measured lean mass. Treat this as a guardrail, not a proven rule.
- 4
Creatine, if you are liftingIndirect evidence only
No completed trial has tested creatine in GLP-1 users. In people doing resistance training generally, creatine adds about +1.1 kg of lean mass over training alone across 35 trials; without exercise, it does nothing for lean mass. Note that creatine also adds 0.5 to 2 kg of water weight, which can mask fat loss on the scale. The first trial of creatine in GLP-1 users was still recruiting in 2026.
- 5
Slower dose titrationSensible, unproven for muscle
Slower escalation is standard for gastrointestinal tolerability and makes it easier to actually eat enough protein. No trial shows it preserves lean mass. Do not let anyone sell it to you as a proven muscle strategy.
- 6
HMBWeak and mixed
The leucine metabolite HMB (~3 g/day) shows small effects in older and clinical muscle-wasting populations, with mixed results, and, like creatine, no data at all in GLP-1 users. It is optional, not a headline recommendation. The same applies to essential amino acids, leucine, omega-3s and vitamin D for muscle specifically, though vitamin D, B12, iron, thiamine and calcium are worth monitoring on GLP-1s for deficiency.
Measure the right things. If you track anything, track strength and function, grip strength, a chair-stand test, your working weights, alongside a DXA if you have access to one, rather than scale weight alone. Consumer bioimpedance scales are hydration sensitive, which makes them especially noisy on these drugs.
The muscle-preserving drugs: striking scans, no strength data yet
A new class of drugs aims to change the ratio itself. Myostatin and the activins are natural brakes on muscle growth, acting through activin type II receptors. Block the brake, and muscle can be maintained, or even grown, while fat is lost. Three agents now have Phase 2 data alongside GLP-1s. All of them share the same limits: none is approved for obesity or muscle preservation, every result is DXA based, and none has yet shown that people get stronger or function better.
Bimagrumab Phase 2 · Not approved for obesity
Activin type II receptor blocker (Eli Lilly) · IV infusion every 4 weeks
In the BELIEVE trial (n = 507, 48 weeks), semaglutide alone lost 3.9 kg of lean mass and 9.6 kg of fat. The high-dose bimagrumab combination lost only 1.3 kg of lean while losing 15.6 kg of fat. 92.3% of the combination’s weight loss was fat, versus 71.1% on semaglutide alone. By week 72 the combination had lost 22.1% of body weight with lean mass down just 2.9%; bimagrumab alone actually gained lean mass (+2.5%) while losing fat. An earlier trial in type 2 diabetes showed the same signature: fat mass −20.5% with lean mass up 3.6%.
- Lean loss, combo vs sema alone
- −1.3 kg vs −3.9 kg (wk 48)
- Fat share of loss
- 92.3% vs 71.1%
- Watch-outs
- Muscle spasms, diarrhea, acne; an LDL-cholesterol rise (+0.47 mmol/L) reported in a pooled analysis of earlier trials
Status as of late 2026: no Phase 3 obesity trial listed, and a planned bimagrumab + tirzepatide trial in type 2 diabetes was withdrawn before enrolment. One figure to hold loosely: secondary summaries of BELIEVE’s week-72 semaglutide lean change differ slightly (−7.4% vs −7.9%); this article uses −7.4%.
Apitegromab Phase 2 for this use · Approved only for spinal muscular atrophy
Selective inhibitor of myostatin activation (Scholar Rock) · IV every 4 weeks, added to tirzepatide
In EMBRAZE (n = 102, 24 weeks), adding apitegromab to tirzepatide cut lean loss from 3.5 kg to 1.6 kg, 1.9 kg less lean loss (95% CI 1.2 to 2.7), a 54.9% retention, bringing the lean share of weight lost down from 30.2% to 14.6%, with similar total weight loss in both arms.
- Lean loss
- −1.6 kg vs −3.5 kg
- Lean share of loss
- 14.6% vs 30.2%
- Watch-outs
- No improvement in strength, physical function or cardiometabolic markers at 24 weeks; 8 weeks after stopping, the lean advantage had shrunk from 1.9 kg to 0.9 kg
Design caveats: this was a proof-of-concept trial powered at 75% for a 2 kg difference, analyzed at a two-sided α of 0.20 without multiplicity adjustment. Apitegromab was FDA approved in September 2026 as Isembyld, for spinal muscular atrophy only. That approval is not for weight loss, and the drug is not prescribable for muscle preservation.
Trevogrumab Phase 2 · Investigational
Anti-myostatin (anti-GDF8) antibody (Regeneron) · Added to semaglutide in the COURAGE trial
In COURAGE (n ≈ 975 to 1,005, results presented autumn 2026), semaglutide plus placebo lost 7.3% of lean mass over 52 weeks, versus 5.8% with trevogrumab 25 mg and 4.2% with 75 mg, a 42.5% preservation at the higher dose (difference 3.1 percentage points, 95% CI 1.3 to 4.9). An MRI substudy suggested about 70% of thigh muscle volume was preserved. In a higher-dose portion, the lean share of loss fell from 33% on semaglutide alone to 16.8% with trevogrumab 200 mg.
- Lean-mass change
- −4.2% (75 mg) vs −7.3% (sema alone)
- Thigh muscle volume (MRI)
- ~70% preserved
- Watch-outs
- See the safety note below. It concerns the combination arm, not trevogrumab alone
Evidence level: at the time of research, the COURAGE numbers rested on the sponsor’s press release and secondary summaries of the journal publication, not on a full peer-reviewed text verified for this article. Hold them one notch looser than BELIEVE and EMBRAZE. Safety: the trial’s triple-therapy arm (trevogrumab plus garetosmab, a different antibody, plus semaglutide) recorded 14 serious adverse events among 149 participants, 48 discontinuations and 2 deaths, with no causal association identified. Those events belong to the triple combination, not to trevogrumab alone, but they should not be omitted, and they are part of why this class is not ready for routine use.
What about testosterone, SARMs or growth hormone, which circulate online for exactly this purpose? There is no randomized evidence for any of them in GLP-1 users, and each carries significant safety and regulatory issues. They are not an evidence-based strategy, whatever the forums say.
These agents prove the fat-to-lean ratio is modifiable. That matters. But they prove it on DXA scans, over 24 to 72 weeks, in Phase 2, without showing preserved strength or function, and with open questions about cost, infusions, lipids, long-term safety, and whether preserved lean mass persists after the drug stops. Promising is the right word. Available is not.
Six claims you will hear, checked
Tap any claim for the verdict and the evidence behind it.
The ~38% figure from STEP-1 is lean mass, muscle plus water, organs and connective tissue. Muscle is about half of lean mass, so the muscle share is roughly 20% of weight lost. The confusion between lean mass and muscle mass is the single biggest distortion in this debate.
Pooled data put the lean share at 25 to 39% on incretin drugs versus 26.2% for intensive lifestyle intervention, not significantly different (p = 0.42). In SURMOUNT-1 the split on tirzepatide (74% fat / 26% lean) matched placebo almost exactly. What differs is the total amount lost, not the proportion.
An estimated 2 to 3 kg of true muscle within a 15 to 20 kg loss is small for a robust 45-year-old. It is not small for a 75-year-old with sarcopenia losing 25 kg. That can equal more than a decade of age-related loss, and muscle is harder to rebuild after 65. Starting reserve and total loss decide whether this claim is true for you.
Function scores improved in SURMOUNT-1, most studies in older adults show no significant strength change, and muscle quality (fat infiltration) improves on MRI. But in T-REx, tirzepatide alone caused a 6 to 9% strength loss over 40 weeks in people aged 50 to 70. “Preserved” holds on average in younger populations, and fails without training in the one direct strength trial.
The joint advisory states plainly that higher protein without structured resistance training is likely inadequate to preserve muscle. And the protein target itself (1.2 to 1.6 g/kg/day) is proposed, not proven in GLP-1 users. Training is the intervention with the randomized trial; protein is its support act. Even together, T-REx lifters still lost 3.6 kg of lean tissue.
Weight regain after stopping is predominantly fat, and lean regain is incomplete, especially without training. In the S-LiTE follow-up, only the groups that had exercised were still holding a ≥10% loss a year after treatment ended. One honest limit: the body composition of regain on modern GLP-1s specifically is understudied, so the size of this ratchet effect is not yet pinned down.
Bimagrumab, apitegromab and trevogrumab all shift body composition impressively in Phase 2, up to 92% of weight lost as fat with bimagrumab plus semaglutide. But none is approved for this use, none has shown a strength or function benefit, and apitegromab’s lean advantage halved within 8 weeks of stopping. DXA composition is a surrogate; function is the outcome that matters.
What we still do not know
An honest article ends with its gaps. As of this research (15 November 2026), the literature has no answer to any of the following. Anyone who claims otherwise is ahead of the evidence:
- A “safe” threshold for lean loss. No validated cut-off exists below which lean loss is harmless.
- Falls, fractures and frailty as outcomes. No GLP-1 trial has measured them as primary endpoints; direct evidence in adults over 75, or with established frailty or sarcopenia, is essentially absent.
- What regain is made of. The body composition of weight regained after stopping semaglutide or tirzepatide specifically has not been well characterized.
- Whether slower titration preserves muscle. Plausible, sensible for tolerability, and untested for lean mass.
- Creatine or HMB on GLP-1s. Trials are recruiting (the first creatine trial, with supervised resistance training, is due around 2027); there are no results to cite.
- The trials that would settle protection. LEAN-PREP (232 adults; semaglutide/tirzepatide with resistance training, protein, both, or control; MRI quadriceps as the primary outcome) is not due to complete until 2029, and RESIST (tirzepatide plus resistance training) until 2027.
GLP-1s do not uniquely destroy muscle. They produce large, fast weight loss. Large, fast weight loss always takes lean tissue with it, at roughly the same proportion as every other effective method. About half of that lean loss is real muscle, amounting to roughly 5 to 6 kg of lean tissue in the landmark trials. For most people that is a manageable cost next to proven cardiovascular and metabolic benefit. For older adults and anyone starting with little muscle, it is a cost that deserves a plan: lift two to three times a week, eat protein toward 1.2 to 1.6 g/kg/day, keep the rate of loss sane, and measure strength, not just the scale. Protein alone was never going to be the whole answer. It is not even the first item on the list.
Sources
- Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. 2026;28:4818 to 4827. dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70666
- Sattar N, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis. Lancet Diabetes & Endocrinology. 2025;13:482 to 493. pubmed.ncbi.nlm.nih.gov/40318682
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes, Obesity and Metabolism. 2025;27(5):2720 to 2729. pmc.ncbi.nlm.nih.gov/articles/PMC11965027
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition. 2025;122:344 to 367. pmc.ncbi.nlm.nih.gov/articles/PMC12304835
- Beavers KM, et al. GLP-1 receptor agonist, based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity. 2025;33:225 to 237. pubmed.ncbi.nlm.nih.gov/39710882
- Chaston TB, Dixon JB, O’Brien PE. Changes in fat-free mass during significant weight loss: a systematic review. International Journal of Obesity. 2007;31:743 to 750. pubmed.ncbi.nlm.nih.gov/17075583
- GLP-1 receptor agonist therapy and skeletal muscle: a narrative review synthesizing adult evidence with implications for older adults. Journal of Frailty & Aging. 2026. pmc.ncbi.nlm.nih.gov/articles/PMC13499509
- Xu J, Maier AB, et al. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2022;68:361 to 376. pubmed.ncbi.nlm.nih.gov/34315158
- Green DJ, et al. Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (T-REx). Nature Medicine. Published online 9 November 2026. pubmed.ncbi.nlm.nih.gov/43003902
- Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment (S-LiTE follow-up). eClinicalMedicine. 2024;69:102475. pubmed.ncbi.nlm.nih.gov/38544798
- Heymsfield SB, et al. Bimagrumab plus semaglutide, alone or in combination, for the treatment of obesity (BELIEVE): a randomised phase 2 trial. Nature Medicine. 2026;32:869 to 882. nature.com/articles/s41591-026-04204-0
- Heymsfield SB, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Network Open. 2021;4:e2033457. pubmed.ncbi.nlm.nih.gov/33439265
- Pratley RE, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss (EMBRAZE): a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine. 2026. nature.com/articles/s41591-026-04440-4
- Regeneron Pharmaceuticals. Phase 2 COURAGE trial: trevogrumab + semaglutide (results as announced, 1 October 2026; numbers from sponsor release and secondary summaries, see the evidence-level note in Section 5). drugs.com COURAGE announcement
- Also cited in text: Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM. 2021;384:989 to 1002 · Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM. 2022;387:205 to 216 · Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. NEJM. 2021;384:1719 to 1730 · Villareal DT, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. NEJM. 2017;376:1943 to 1955 · Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM. 2023;389:2221 to 2232 · Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with GLP-1, based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(Suppl 4):16 to 27 · Desai I, et al. Creatine supplementation and resistance training: meta-analysis. Journal of Strength and Conditioning Research. 2024 · Garthe I, et al. Effect of two different weight-loss rates on body composition and performance in elite athletes. International Journal of Sport Nutrition and Exercise Metabolism. 2011;21:97 to 104.
This article is educational and does not replace medical advice. GLP-1 and GIP/GLP-1 medicines are prescription drugs with real risks and contraindications; whether any of them is appropriate for you belongs in an evaluation with your own physician, not in an article.


